当前位置: X-MOL 学术Adv. Drug Deliver. Rev. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Bench-to-bedside translation of dendrimers: Reality or utopia? A concise analysis
Advanced Drug Delivery Reviews ( IF 16.1 ) Pub Date : 2017-11-16 , DOI: 10.1016/j.addr.2017.11.007
Serge Mignani , João Rodrigues , Helena Tomas , René Roy , Xiangyang Shi , Jean-Pierre Majoral

Nanomedicine, which is an application of nanotechnologies in healthcare is developed to improve the treatments and lives of patients suffering from a range of disorders and to increase the successes of drug candidates. Within the nanotechnology universe, the remarkable unique and tunable properties of dendrimers have made them promising tools for diverse biomedical applications such as drug delivery, gene therapy and diagnostic. Up-to-date, very few dendrimers has yet gained regulatory approval for systemic administration, why? In this critical review, we briefly focus on the list of desired basic dendrimer requirements for decision-making purpose by the scientists (go/no-go decision), in early development stages, to become clinical candidates, and to move towards Investigational New Drugs (IND) application submission. In addition, the successful translation between research and clinic should be performed by the implementation of a simple roadmap to jump the ‘valley of death’ successfully.



中文翻译:

树状分子从台到床的翻译:现实还是乌托邦?简洁的分析

纳米医学是将纳米技术应用于医疗保健领域,旨在改善患有多种疾病的患者的治疗和生活,并提高候选药物的成功率。在纳米技术领域,树枝状聚合物的独特和可调节的特性使其成为用于多种生物医学应用(如药物递送,基因治疗和诊断)的有前途的工具。迄今为止,很少有树状大分子获得全身给药的监管批准,这是为什么呢?在这篇重要的综述中,我们简要地关注了科学家在决策的早期阶段(通过/不通过的决策)出于决策目的所需的基本树状大分子要求的清单,以使其成为临床候选药物并迈向研究性新药(IND)申请提交。此外,

更新日期:2017-11-16
down
wechat
bug